Non-exclusive discount agreement for Interferon beta-1a drug

Summary

The tender concerns a non-exclusive discount agreement for Interferon beta-1a (subcutaneous use). DAK-Gesundheit intends to conclude rebate contracts with as many interested pharmaceutical companies as possible under this framework, for the ATC L03AB07 medicines. The rebate agreement will take effect on 01 November 2026 and end on 31 October 2028, and will terminate automatically if an exclusive contract comes into force. The procurement falls under supplies and invites participation from pharmaceutical companies.